Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.07
NAS:ENDP's Cash to Debt is ranked lower than
95% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. NAS:ENDP: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ENDP' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.07

Equity to Asset 0.29
NAS:ENDP's Equity to Asset is ranked lower than
88% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:ENDP: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ENDP' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.77
Current: 0.29

0.08
0.77
F-Score: 5
Z-Score: 1.16
M-Score: -2.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -8.48
NAS:ENDP's Operating margin (%) is ranked lower than
80% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.81 vs. NAS:ENDP: -8.48 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ENDP' s 10-Year Operating margin (%) Range
Min: -31.17   Max: 38.19
Current: -8.48

-31.17
38.19
Net-margin (%) -12.02
NAS:ENDP's Net-margin (%) is ranked lower than
81% of the 647 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.82 vs. NAS:ENDP: -12.02 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ENDP' s 10-Year Net-margin (%) Range
Min: -79.44   Max: 24.67
Current: -12.02

-79.44
24.67
ROE (%) -12.18
NAS:ENDP's ROE (%) is ranked lower than
77% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. NAS:ENDP: -12.18 )
Ranked among companies with meaningful ROE (%) only.
NAS:ENDP' s 10-Year ROE (%) Range
Min: -113.34   Max: 26.98
Current: -12.18

-113.34
26.98
ROA (%) -3.27
NAS:ENDP's ROA (%) is ranked lower than
73% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. NAS:ENDP: -3.27 )
Ranked among companies with meaningful ROA (%) only.
NAS:ENDP' s 10-Year ROA (%) Range
Min: -39.34   Max: 17.45
Current: -3.27

-39.34
17.45
ROC (Joel Greenblatt) (%) -32.65
NAS:ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.39 vs. NAS:ENDP: -32.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ENDP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -116.32   Max: 753.26
Current: -32.65

-116.32
753.26
Revenue Growth (3Y)(%) -4.60
NAS:ENDP's Revenue Growth (3Y)(%) is ranked lower than
76% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NAS:ENDP: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ENDP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.6   Max: 30.3
Current: -4.6

-4.6
30.3
» NAS:ENDP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ENDP Guru Trades in Q2 2014

Chuck Royce 1,300 sh (New)
Joel Greenblatt 88,697 sh (New)
Paul Tudor Jones 177,373 sh (+4959.13%)
Louis Moore Bacon 15,334 sh (+173.72%)
Larry Robbins 3,930,472 sh (+100.11%)
Wallace Weitz 876,670 sh (+75.01%)
Jana Partners 3,199,017 sh (+24.80%)
Julian Robertson 22,800 sh (unchged)
John Griffin 6,766 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Steve Mandel Sold Out
John Griffin 6,815,000 sh (-14.81%)
Mario Gabelli 23,900 sh (-21.77%)
» More
Q3 2014

ENDP Guru Trades in Q3 2014

Larry Robbins 5,658,326 sh (+43.96%)
John Griffin 676,600 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
Jana Partners Sold Out
Mario Gabelli 22,900 sh (-4.18%)
Julian Robertson 20,300 sh (-10.96%)
John Griffin 5,698,528 sh (-16.38%)
Wallace Weitz 721,950 sh (-17.65%)
Joel Greenblatt 13,716 sh (-84.54%)
Paul Tudor Jones 19,281 sh (-89.13%)
» More
Q4 2014

ENDP Guru Trades in Q4 2014

George Soros 1,748,729 sh (New)
RS Investment Management 351,943 sh (New)
Pioneer Investments 389,510 sh (New)
Larry Robbins 6,851,326 sh (+21.08%)
Wallace Weitz 767,530 sh (+6.31%)
John Griffin 676,600 sh (unchged)
Paul Tudor Jones Sold Out
Julian Robertson Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 19,900 sh (-13.10%)
John Griffin 4,409,000 sh (-22.63%)
» More
Q1 2015

ENDP Guru Trades in Q1 2015

Dodge & Cox 2,560 sh (New)
Louis Moore Bacon 38,262 sh (New)
Steve Mandel 3,270,117 sh (New)
Pioneer Investments 512,974 sh (+31.70%)
George Soros 2,217,176 sh (+26.79%)
John Griffin 4,939,000 sh (+12.02%)
RS Investment Management 356,720 sh (+1.36%)
Larry Robbins 6,845,883 sh (-0.08%)
Wallace Weitz 747,530 sh (-2.61%)
Mario Gabelli 14,650 sh (-26.38%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Endo International PLC

Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector
During the campaigns in the recently concluded midterm elections, incumbent Democrats were reluctant to speak of Obamacare, almost as hesitant as they were to be seen with the president, on the campaign trail. Read more...

Ratios

vs
industry
vs
history
Forward P/E 16.31
ENDP's Forward P/E is ranked higher than
65% of the 427 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.72 vs. ENDP: 16.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.70
ENDP's P/B is ranked higher than
50% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. ENDP: 3.70 )
Ranked among companies with meaningful P/B only.
ENDP' s 10-Year P/B Range
Min: 1.48   Max: 17.5
Current: 3.7

1.48
17.5
P/S 4.20
ENDP's P/S is ranked lower than
67% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. ENDP: 4.20 )
Ranked among companies with meaningful P/S only.
ENDP' s 10-Year P/S Range
Min: 1.03   Max: 6.1
Current: 4.2

1.03
6.1
PFCF 30.80
ENDP's PFCF is ranked higher than
58% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.02 vs. ENDP: 30.80 )
Ranked among companies with meaningful PFCF only.
ENDP' s 10-Year PFCF Range
Min: 4.6   Max: 264.07
Current: 30.8

4.6
264.07
POCF 26.29
ENDP's POCF is ranked higher than
51% of the 444 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.61 vs. ENDP: 26.29 )
Ranked among companies with meaningful POCF only.
ENDP' s 10-Year POCF Range
Min: 3.96   Max: 90.18
Current: 26.29

3.96
90.18
Current Ratio 1.55
ENDP's Current Ratio is ranked lower than
69% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ENDP: 1.55 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.55
Current: 1.55

1.07
3.55
Quick Ratio 1.37
ENDP's Quick Ratio is ranked lower than
60% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. ENDP: 1.37 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s 10-Year Quick Ratio Range
Min: 0.91   Max: 3.34
Current: 1.37

0.91
3.34
Days Inventory 118.04
ENDP's Days Inventory is ranked lower than
52% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. ENDP: 118.04 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s 10-Year Days Inventory Range
Min: 66.62   Max: 157.75
Current: 118.04

66.62
157.75
Days Sales Outstanding 150.47
ENDP's Days Sales Outstanding is ranked lower than
87% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. ENDP: 150.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s 10-Year Days Sales Outstanding Range
Min: 62.07   Max: 164.01
Current: 150.47

62.07
164.01

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.10
ENDP's Price/DCF (Projected) is ranked higher than
62% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. ENDP: 2.10 )
Ranked among companies with meaningful Price/DCF (Projected) only.
ENDP' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 2.19
Current: 2.1

0.4
2.19
Price/Median PS Value 1.60
ENDP's Price/Median PS Value is ranked lower than
57% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. ENDP: 1.60 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.94
Current: 1.6

0.39
2.94
Price/Peter Lynch Fair Value 73.20
ENDP's Price/Peter Lynch Fair Value is ranked lower than
99% of the 219 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ENDP: 73.20 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ENDP' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.38   Max: 27.58
Current: 73.2

0.38
27.58
Earnings Yield (Greenblatt) -1.20
ENDP's Earnings Yield (Greenblatt) is ranked lower than
70% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. ENDP: -1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ENDP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.2   Max: 25.4
Current: -1.2

-1.2
25.4
Forward Rate of Return (Yacktman) 18.19
ENDP's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.59 vs. ENDP: 18.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
ENDP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 63.3
Current: 18.19

3.3
63.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EO7.Germany, ENL.Canada,
Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
Endo International Posts Upbeat Q1 Results May 13 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
Weekly Insider Sells Highlight: ANTM, ENDP, QVCA, TOL Apr 12 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 

More From Other Websites
Activist Keith Meister’s New Additions to His Fund’s Portfolio Include Yum! Brands, Inc. (YUM),... Jun 02 2015
Business Highlights Jun 01 2015
Tailwinds for US Equities Today May 27 2015
Will This Analyst Action Affect Endo Int'l. (ENDP) Stock? May 22 2015
ENDO INTERNATIONAL PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... May 21 2015
ENDO INTERNATIONAL PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 20 2015
7 Biotech Stocks Moving Off The UBS Healthcare Conference May 19 2015
Pharma buying spree continues May 19 2015
Company News for May 19, 2015 - Corporate Summary May 19 2015
Fed afraid of everything: LaVorgna May 19 2015
Jim Cramer -- Stock Market's Takeover Frenzy Won't End Anytime Soon May 19 2015
DKS has a golf problem: Cramer May 19 2015
First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate... May 19 2015
First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate... May 19 2015
First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate... May 19 2015
Overheard: For Bankers, a Means to an Endo May 18 2015
[$$] Endo to Buy Par Pharma for About $8 Billion May 18 2015
PRESS DIGEST- New York Times business news - May 19 May 18 2015
PRESS DIGEST- Financial Times - May 19 May 18 2015
Ann and Endo big market movers May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK